Clover raises RMB62.8M in series A

Clover Biopharmaceuticals Inc. (Chengdu, China) raised RMB62.8 million ($9.5 million) in a series A round led by Tianhe Life Sciences Venture Fund.

Clover is developing covalently trimerized fusion proteins using its Timer-Tag technology to target pathways that depend on the formation of trimers to initiate downstream signaling, such as TNF superfamily proteins and enveloped RNA virus antigens. ...